AnaptysBio approves spin-off of First Tracks Biotherapeutics; distribution set for April 20, 2026

ANAPTYSBIO, INC

Anaptys stockholders to receive one share of First Tracks Bio (TRAX) per ANAB share held on April 6, 2026; distribution expected pre-market April 20, 2026.
First Tracks Bio launches with $180M cash ($100M from Anaptys + $80M from private placement at $13.81/share) and a two-year cash runway.
Post-spin Anaptys to manage Jemperli (GSK) and imsidolimab (Vanda) royalties; virtual model with <10 FTEs and <$10M annual opex; $100M stock repurchase plan authorized.
Susannah Gray (former Royalty Pharma CFO) appointed to Anaptys board; Dennis Mulroy and Eric Loumeau to exit with separation agreements.
Anaptys terminates existing ATM sales agreement with TD Securities.

item 1.01 item 1.02 item 5.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ANAPTYSBIO, INC entered into Purchase Agreement with certain third party investors valued at approximately $80 million (effective 2026-03-26).

Action: entry
Agreement: equity purchase
Counterparty: certain third party investors
Value: approximately $80 million
Effective: 2026-03-26

Exact text from the filing

On March 26, 2026, First Tracks Biotherapeutics and EcoR1 Capital Fund Qualified, L.P. (the “Selling Stockholder”) entered into a purchase agreement (the “Purchase Agreement”) with certain third party investors (collectively, the “Investors”), pursuant to which SpinCo agreed to issue and sell an aggregate 5,791,478 shares of SpinCo’s common stock

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ANAPTYSBIO, INC terminated Sales Agreement with TD Securities (USA) LLC (effective 2024-11-05).

Action: termination
Agreement: atm program
Counterparty: TD Securities (USA) LLC
Effective: 2024-11-05

Exact text from the filing

As previously disclosed, on November 5, 2024, the Company entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC (the “Agent”), pursuant to which the Company could issue and sell, from time to time, shares of its common stock, par value $0.001 per share (the “Common Shares”), up to an aggregate offering price equal to the Maximum Amount (the “ATM Program”). The Company has issued a termination letter to the Agent to terminate the Sales Agreement.

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001193125-26-127783

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.